poisar

Stocks · News reference

Novartis Receives CHMP Opinion For Cosentyx In Adolescents Aged 12+ With Hidradenitis Suppurativa

BenzingaBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncPrecedence Research

    Pharmaceutical Market to Reach USD 3.20 Trillion by 2035 as Obesity and Oncology Drugs Lead Growth and U.S. Pricing Deals and Tariffs Reshape Manufacturing

    The global pharmaceutical market is valued at USD 1.88 trillion in 2026 and is projected to reach USD 3.20 trillion by 2035 at a CAGR of 6.10%. Growth is concentrated in obesity and oncology therapies, with U.S. pricing deals and Section 232 tariffs reshaping manufacturing. North America holds 42% of the market, while companies with strong positions in GLP-1 medicines and cancer therapies are growing significantly faster than the market.

  2. Globenewswire IncNovartis

    Novartis Cosentyx® becomes first and only FDA-approved anti-IL-17 biologic for people with polymyalgia rheumatica (PMR)

    The FDA approved Novartis's Cosentyx (secukinumab) 150 mg for treating polymyalgia rheumatica in adults with inadequate response to or intolerance of corticosteroids. In the Phase III REPLENISH trial, Cosentyx doubled sustained remission rates (40.5% vs 20.5%) compared to placebo and demonstrated steroid-sparing effects. This marks the 11th US indication for Cosentyx and the first anti-IL-17 biologic approved for PMR, offering an alternative to long-term steroid use which carries significant health risks.